Gisbert Javier P, Gaffney Karl, Young David, Ebbers Hans C, Girolomoni Giampiero
Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Rheumatology Department, Norfolk and Norwich Hospitals NHS Foundation Trust, Norwich, UK.
Expert Opin Biol Ther. 2022 Feb;22(2):109-121. doi: 10.1080/14712598.2022.2012146. Epub 2021 Dec 31.
This review provides an overview of data from trials and real-world studies available for SB5 (Imraldi) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology.
A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken.
Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immune-mediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments.
本综述概述了SB5（英莫单抗）在三个主要治疗领域（风湿病学、胃肠病学和皮肤病学）的试验和真实世界研究数据。
对有关SB5疗效/有效性、安全性和免疫原性数据的出版物进行了文献检索。
临床研究证据表明，生物类似药SB5是参比阿达木单抗的一种安全有效的替代药物。鉴于患有免疫介导的炎症性疾病（如炎性关节炎、炎性肠病和银屑病）的患者通常需要长期生物治疗，生物类似药（如SB5）可降低医疗成本，同时增加有效治疗的可及性。
